Gritstone announces presentations on next gen COVID-19 vaccine

Gritstone bio announced the presentation of results from three ongoing Phase 1 studies evaluating its self-amplifying mRNA vaccine candidates against COVID-19 at IDWeek 2023, occurring October 11-15, 2023, in Boston, MA. Gritstone will present further follow up data from the CORAL-CEPI and CORAL-BOOST studies. CORAL-CEPI Presentation: Durable Immune Response Induced by Self-amplifying mRNA SARS-CoV-2 Vaccine Candidates in Vaccine-naive HIV Negative and People Living with HIV Populations. Results presented from Group A, B and C demonstrated: All doses were well tolerated in both HIV-negative participants and PLWH irrespective of SARS-CoV-2 serostatus at baseline. High IgG and neutralizing antibody responses were induced and sustained for at least 12 months. CORAL-BOOST Presentation: Durable Immune Response Induced by a Self-amplifying mRNA SARS-CoV-2 Vaccine Candidate in Adults Previously Vaccinated with mRNA or Adenovirus. Results presented from cohorts 1 – 4 demonstrated: Vaccine candidate was well tolerated as a booster regardless of primary vaccination series. Robust, durable binding and high neutralizing antibodies were induced and sustained for up to at least 12 months against SpikeD614G and variants of concern. Broad T cell responses induced against Spike and non-Spike T cell epitopes included in the vaccine. Use of T cell receptor sequencing assays to assess T cell response breadth. CORAL-NIH Presentation: An Interim Report of the Safety, Reactogenicity, and Immunogenicity of a Self-amplifying mRNA COVID-19 Vaccine GRT-R910 as a Booster in Healthy Adults. Results presented from adults across all age groups and dose levels demonstrated: Vaccine candidate was well-tolerated with no safety signals identified. Durable boosting of humoral immune responses to Spike and variants of concern, and high neutralizing antibody responses to at least 6 months were observed for all vaccine groups. Results are consistent across Phase 1 trials of GRT-R910 and similar vaccines.